重复氯胺酮输注治疗慢性创伤后应激障碍的随机对照试验
该随机对照试验将30例慢性PTSD患者按1:1分配接受6次氯胺酮(0.5 mg/kg)或咪达唑仑(0.045 mg/kg)输注,疗程2周;氯胺酮组CAPS-5和MADRS总分改善显著优于咪达唑仑组,且耐受性良好,无严重不良事件。
要点
- 重复氯胺酮输注可显著降低慢性PTSD症状严重度,第2周CAPS-5总分较对照组低11.88分。
- 氯胺酮输注总体耐受良好,未报告严重不良事件。
核心结论
- 重复静脉氯胺酮输注可显著改善慢性PTSD患者的症状严重度,且耐受性良好,无严重不良事件。
研究设计与样本
- 随机对照试验,30例慢性PTSD患者按1:1随机接受6次氯胺酮(0.5 mg/kg)或咪达唑仑(0.045 mg/kg)静脉输注,历时2周。
主要发现
- 第2周时氯胺酮组CAPS-5总分较咪达唑仑组低11.88分(SE=3.96,d=1.13,95% CI=0.36, 1.91)。
- 氯胺酮应答者中位疗效丧失时间为27.5天。
- 氯胺酮组MADRS总分改善显著优于咪达唑仑组。
关键数值与推荐
- 氯胺酮剂量0.5 mg/kg,咪达唑仑剂量0.045 mg/kg,各输注6次。
- 主要结局为CAPS-5从基线至第2周的变化,次要结局包括IES-R、MADRS及副作用。
临床怎么用
- 重复氯胺酮输注可作为慢性PTSD的潜在短期治疗选择,需关注疗效维持时间约27.5天。
局限性
- 样本量较小(N=30),需进一步研究验证氯胺酮治疗慢性PTSD的完整潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors' previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion. The present study is the first randomized controlled trial to test the efficacy and safety of repeated intravenous ketamine infusions for the treatment of chronic PTSD. METHODS: Individuals with chronic PTSD (N=30) were randomly assigned (1:1) to receive six infusions of ketamine (0.5 mg/kg) or midazolam (0.045 mg/kg) (psychoactive placebo control) over 2 consecutive weeks. Clinician-rated and self-report assessments were administered 24 hours after the first infusion and at weekly visits. The primary outcome measure was change in PTSD symptom severity, as assessed with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), from baseline to 2 weeks (after completion of all infusions). Secondary outcome measures included the Impact of Event Scale-Revised, the Montgomery-Åsberg Depression Rating Scale (MADRS), and side effect measures. RESULTS: The ketamine group showed a significantly greater improvement in CAPS-5 and MADRS total scores than the midazolam group from baseline to week 2. At week 2, the mean CAPS-5 total score was 11.88 points (SE=3.96) lower in the ketamine group than in the midazolam group (d=1.13, 95% CI=0.36, 1.91). Sixty-seven percent of participants in the ketamine group were treatment responders, compared with 20% in the midazolam group. Among ketamine responders, the median time to loss of response was 27.5 days following the 2-week course of infusions. Ketamine infusions were well tolerated overall, without serious adverse events. CONCLUSIONS: This randomized controlled trial provides the first evidence of efficacy of repeated ketamine infusions in reducing symptom severity in individuals with chronic PTSD. Further studies are warranted to understand ketamine's full potential as a treatment for chronic PTSD.
引用
- Feder A, Costi S, Rutter SB, et al. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Am J Psychiatry. 2021. PMID: 33397139. doi:10.1176/appi.ajp.2020.20050596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。